"The leucovorin shortage will end. I don't know when, but the generic-drug makers will get their manufacturing issues sorted out." (from the Motley Fool Article).
The generic problem appears to be Spectrum Phama.'s (SPPI) problem. I didn't see
anything new concerning Amarin.
It's Halloween...don't SCARE yourself out of your position!
Classen? LOL. Been shot down by peers and DOD on his stance that vaccines cause diabetes. Used to work for Preceptive. Preceptive, per stocktwits, had an SEC action for short selling. Just saying:
2. From January 2005 through December 2005, Perceptive violated Rule 105 of Regulation M with respect to five repeat securities offerings. In each case, Perceptive sold securities short within five business days before the pricing of the offering, and then covered the short position, in whole or in part, with shares purchased in the offering. As a result, Perceptive obtained unlawful profits of $245,902.34."
Sentiment: Strong Buy
Amarin (devastating) REALITY check late October 2012!:
ONE unprofitable product (a decades year old generic Japanese fish-oil)? Check
No other pipeline? Check
No R&D? Check
No large scale approved API supply? Check
No NCE? Check
Highly dubious IP situation? Check
No sales force? Check
No big pharma partner? Check
Massive insider selling? Check
Totally unrealistic analyst estimates and price targets? Check
Fully loaded wtih dumb institutional and retail suc'ers? Check
No real patents? Check
"According to Summer Street analyst Bart Classen, patent coverage on Amarin's Vascepa remains "very narrow". The implication is that a generic form of the drug could be submitted which isn't covered by the patents, then submitted for FDA approval using a 505(b)(2)* application, a variant of the 505(b) new chemical entity (NCE) app.
The generic pharmas may be able to skip over doing large pivotal studies if submitted under the 505(b)(2) app, noted Classen."